General / Health: The drug "Larotrectinib" does not completely treat cancer and does not replace surgical and chemical treatments.

Friday 1440/3/22 corresponding to 2018/11/30

Riyadh, November 29, 2018
The Ministry of Health has indicated that Vitrakvi is the trade name of Larotrectinib, which does not treat cancer completely or completely, as was recently mentioned in the media and communication sites. And radiotherapy.
The New England Journal of Medicine has published a study on larotrectinib, which included 55 cancer patients and carriers of the TRK gene mutation, with a complete response rate of 13% and a partial response rate of 62%. Long-term response in all patients where the disease has developed in some study participants and continuous response in 39% of patients after the first year of treatment, and in some patients who have undergone surgery after treatment.
The new treatment has recently been approved by the US Food and Drug Administration to treat specific cancer cases with a specific type of rare genetic mutations (TRK gene). Contains the genetic mutation does not tolerate surgery and cases containing the genetic mutation. There is no alternative appropriate to the treatment and cases that appeared after treatment planning.
//
00: 09T
0261